References:
1.
Masquelier, J. Plant extract with a proanthocyanidins content as a therapeutic
agent having radical scavenging effect and use thereof. U.S. Patent
No. 4,698,360, 1987.
2. Lombard, J., (board certified neurologist), Germano,
C. The Brain Wellness Plan - Breakthrough Medical, Nutritional and Immune-Boosting
Therapies to Prevent and Treat Depression, Alzheimer's Disease, Chronic
Fatigue Syndrome, Attention Deficit Disorder, Multiple Sclerosis, Parkinson's
Disease, Lou Gehrig's Disease. Kensington Pub. Corp., 1998.
3. Masquelier, J. A lifetime devoted to OPC and Pycnogenols.
Alfa Omega Editrice, Pub., 1996.
4. Schwitters, B., Masquelier, J. OPC in practice. Alfa
Omega Editrice, Publishers, 1995.
5. Kilham, C., Masquelier, J. OPC: The miracle antioxidant.
Keats Publishing, Inc., 1997.
6. Mindell, E., et al. Earl Mindells vitamin bible
for the 21st century. Warner Books, Inc., 1999.
7. Passwater, R.A. The antioxidants: the nutrients that
guard your body. Keats Publishing, Inc., 1985.
8.Barilla, J. et al. The nutrition superbook: volume
1: the antioxidants. Keats Publishing, Inc., 1995.
9. Lieberman, S., et al. The real vitamin & mineral
book: going beyond the RDA. Avery Pub., 1990.
10. ___. Inadequate intake of vitamins, particularly
B-1, can result in mental illness. Clin. Neuro, 8 (Jul.--Sep. 1985):286-293.
11. ___. Carpal tunnel syndrome treated with riboflavin
and pyridoxine. Proceedings of the Nat. Acad. of Sc. 81 (Nov. 1984):7076-8.
12. ___. High calorie diets with disproportionately low
intakes of vitamins and minerals may be the source of widespread marginal
malnutrition. Journ of the Amer Col of Nut, 7 (1988):61-67.
13. Facino RM, et al. Free radical scavenging action
and anti-enzyme activities of procyanidines from Vitis vinifera. A mechanism
for their capillary protective action. Arzneimittelforschung, 44: 592-601,
1994.
14. Kuttan R, et al. Collagen treated with catechin becomes
resistant to the action of mammalian collagenase. Experientia, 37: 221-223,
1981.
15. Masquelier, J., et al. Stabilization du collagene
par les oligomeres procyanidoliques. Acta Therapeutica, 7:101-105, 1981.
16. Masquelier, J. Aspects pharmacologiques nouveaux
de certains flavonoides. A Vie Medical 12:1969.
17. Laparra, J., et al. Etude pharmaco-cinetique des
oligomers procyandoliques totaux du raisin. Acta Therapeutica, 4, 1978.
18. Laparra, J., et al. Etude pharmacocinetique des oligomeres
flavonoliques. Plantes med et phyto, Tome XI, pp. 133-142, 1977.
19. Robert A.M.; Groult, N.; Six, C.; Robert, L. Etude
de laction des oligomeres procyanidoliques sur des cellules mesenchymateuses
en culture. Ii lattachment des fibres elastiques aux cellules.
(Study of the effect of procyanidolic oligomers on mesenchymal cells
in culture. Ii attachment of elastic fibers to the cells.) Pat Biol,
(30)6:601-7, 1990.
20. Porter, Lawrence J., Wong Rosalind Y. Chan, Bock
G. The molecular and crystal structure of (+)-2,3-trans-3,4-trans-leucocyanidin
[(2r,3s,+r)-(+)-3,3, 4.4, 5.7-Hexahydroxyflavan] dihydrate,
and comparison of its heterocyclic ring conformation in solution and
the solid state. Journal of the Chemical Society; Perkin Transactions
I 1985. pp. 1413-17.
21. Masquelier, J. Proanthocyanidins et radicaux libres.
1985.
22. Uchida, S., et al. Condensed tannins scavenge active
oxygen free radicals. Med Sci Res, (15) 1987. pp. 831-832.
23. Ariga, T. Radical scavenging action and its mode
in procyanidins b-1 and b-3 from azuki beans to peroxyl radicals. Agric
Biol Chem, 54(10) 1990. pp. 2499-2504.
24. Da Silva, R., et. al. Radical scavenger capacity
of different procyanidins from grape seeds. Presented at a symposium,
Free radicals in biotechnology and medicine. Royal Society
Of Chemistry, London January 1990, pp. 79-80.
25. Bauman, J., Wurm, G., Bruchhausen, F. Hemmung
der prostagladinsynthetase durch flavonoide und phenolderivate im vergleich
nit deren 02 radikalfangereigenschaften Arch Pharm, (Weinheim)
313 (1980) pp. 330-337.
26. Kidd, P.M. Phosphatidylserine: the nutrient that
accelerates all brain functions and counters Alzheimers disease:
Keats Pub. 1998.
27. O'Brien, C., "Answers to ADD," Vitamin
Retailer, March 2002.
28. Cenacchi T, et al. Cognitive decline in the elderly:
A double-blind, placebo-controlled multicenter study on efficacy of
phosphatidylserine administration. Aging, 5: 123133, 1993.
29. Maggioni M, Picotti GB, Bondiolotti GP et al. Effects
of phosphatidylserine therapy in geriatric patients with depressive
disorders. Acta Psychiatr Scand. 81: 265270, 1990.
30. Brambilla, F., Maggioni, M., Panerai, A.E., et al.
Beta-endorphin concentration in peripheral blood mononuclear cells of
elderly depressed patientseffects of phosphatidylserine therapy.
Neuropsychobiology, 34: 1821, 1996.
31. Monteleone P., Maj M., Beinat L., Natale M., Kemali,
D. Blunting by chronic phosphatidylserine administration of the stress-induced
activation of the hypothalamo-pituitary-adrenal axis in healthy men.
Eur J Clin Pharm, 43: 385388, 1992.
32. Cenacchi T, et al., Cognitive decline in the
elderly: A double-blind, placebo-controlled multicenter study on efficacy
of phosphatidylserine administration. Aging, 5, 123-133, 1993
33. Funfgeld, E.W., Baggen, M., Nedwidek, P., Richstein,
B., Mistlberger, G. Double-blind study with phosphatidylserine (PS)
in parkinsonian patients with senile dementia of Alzheimers type
(SDAT). Prog Clin Biol Res, 317:1235-46, 1989.
34. Le Bars, P.L., Katz, M.M., Berman, N., Itil, T.M.,
Freedman, A.M., Schatzberg, F.A. A placebo-controlled, double-blind,
randomized trial of an extract of ginkgo biloba for dementia. Journal
of the Amer Med Assoc, 278 (16):1327-32, 1997.
35. Waagepetersen, H.S., Sonnewald, U., Schousboe, A.
The GABA paradox: multiple roles as metabolite, neurotransmitter, and
neurodifferentiative agent. J Neurochem, 73:133542, 1999.
36. Goddard, A.W., Mason, G.F., Almai, A., Rothman, D.L.,
Behar, K.L., Petroff, O.A.C., Charney, D.S., Krystal, J.H. Reductions
in occipital cortex gaba levels in panic disorder detected with h-magnetic
resonance spectroscopy. Arch Gen Psychiatry, 58:556-561, 2001.
37. Braverman, E., et al. The healing nutrients within:
in facts, findings and new research. Keats, 1987.
38. Cavagnini, F., et al. Effect of acute and repeated
administration of gamma aminobutyric acid (GABA) on growth hormone and
prolactin secretion in man. Acta Endocrinol, 93:14954, 1980.
39. Bhagavan, H.N., et al. The effect of pyridoxine hydrochloride
on blood serotonin and pyridoxal phosphate contents in hyperactive children.
Pediatrics, 1975;55: 437-41.
40. ___. Along with riboflavin, vitamin B-6 deficiency
has a primary role in the cause of emotional disorder. British Journal
of Psychiatry, 141(1982):271-272.
41. ___. Current data suggest that as many as 20 percent
of medically cleared population of outpatient depressives may suffer
from a vitamin B-6 deficit. The authors point out that nutrition, diet
and vitamin levels have received very little attention in the psychiatric
literature. Biological Psychiatry, 9:4 (1984):613-6.
42. ___. Does depressive illness cause vitamin B-6 inadequacy,
or vice-versa? Nut Rep Int, 27 (Apr. 1993):867-873.
43. Martineau, J., et al. Vit. B6, magnesium, and combined
B6-Mg: therapeutic effects. Bio Psy, 20:467-78, 1985.
44. Dolphin, et al. (eds). Vitamin B6: pyridoxal phosphate.
John Wiley & Sons, 1986, chapt. 17.
45. Langseth, L., et al. Glucose tolerance and hyperkinesis.
Food and Cosm Toxicology, 16 Aug. 1977.
46. Bekaroglu, M., Aslan, Y., Gedik, Y., Deger, O., et
al. Relationships between serum free fatty acids and zinc, and attention
deficit disorder: a research note. J. Child Psychol. Psychiatry 1996
Fed; 37 (2):225-7.
47. Facino, R.M., et al. Free radical scavenging action
and anti-enzyme activities of procyanidines from vitis vinifera. A mechanism
for their capillary protective action. Arzneimittelforschung, 44: 592-601,
1994.
48. Kuttan, R., Donnelly, P.V., Di Ferrante, N. Collagen
treated with catechin becomes resistant to the action of mammalian collagenase.
Experientia, 37: 221-223, 1981.
49. Masquelier, J. Procyanidolic oligomers. J Parums
Cosm Arom, 95: 89-97, 1990.
50. Tixier, J.M., et al. Evidence by in vivo and in vitro
studies that binding of pycnogenols to elastin affects its rate of degradation
by elastases. Biochem Pharmacol, 33: 3933-3939, 1984.
51. Kakegawa, H., et al. Chem. Pharm. Bull. 33:5079,
1985.
52. Harmand, M.F., Blanquet, P. The fate of total flavanolic
oligomers extracted from vitus vinifera l. in the rat. European
Journal of Drug Metabolism and Pharmaccokinetics. 1978, No. 1 pp. 15-30.
53. Delrieu, P., Ding J., Escande, B., Samain, D. Free-radical
scavenging activity of proanthocyanidolic oligomers encapsulated in
glycospheres: an in vivo and in vitro study. Cosmetology Department
& S Biovectors, Ramonville St. Agne France. pp. 1-9.
54. Meunier, M.T., Villie, F., et al. Inhibition of angiotensin
i converting enzyme by flavanolic compounds: in vitro and in vivo studies.
Planta Medica, May 26, 1986. pp. 12-15.
55. Barbier, A., et al. Activite angioprotectrice des
oligomeres procyanidolques chez lanimal-oedenme de la patte. Sanofi
Res Toul Cedex Fr, pp31-40.
56. Barbier, A., et al. Activite angioprotectrice des
oligomeres procyanidolques chez lanimal-activite aniagoniste vis-a-vis
des mediateurs de linflamation. Sanofi Res Toul Cedex Fr, pp.
31-40.
57. Dubos, C., Durst, G., Hugonot, H. Evolution de la
resistance capillaire, spontanement ou artificiellement diminuee par
laction dune substance capillaro-toxique chez des personnes
agees--action benefique dun agnet actif sur la micro-circulation:
lEndotelon. Inform. Therapeut. 1980. pp. 302-305.
58. Dartenuc, J.Y., et al. Resistance capillaire en geriatrie
etude dun microangioprotecteur-Endotelon. Bordeaux Med. 13:903-7,
1990.
59. Lagrue, G., Olivier-Martin, F., Grillot, A. Etude
des effets des oligomeres du procyanidol sur las resistance capillaire
dand lhypertension arterielle et certaines nephropathies.
Sen. Hosp. Paris 18-25 Septembre, 1981.
60. Beylot, C., Bioulac, P. Essai therapeutique dun
angioprotecteur peripherique, lEndotelon. Actualite Therapeutique
Gaz. Med. de France (87)22:2919-24, 1980.
61. Lesbre, F.X., Tigaud, J.D. Effect de lEndotelon
sur lindice de fragilite capillaire dan une population specifique:
les sujets cirrhotiques. Gaz. Med. de France, (90)24 1983.
62. Sarrat, L. Abord therapeutique des troubles fonctionnels
des membres inferieurs par un microangioprotecteur lEndotelon.
Bordeaux Med, 11:685-8, 1981.
63. Delacroix, P. Etude en double aveugle de lEndotelon
dans linsuffisance veineuse chronique. Therapeutique, la Revue
de Medicine, (27-28) Sept. 1981. pp. 1793-1802.
64. Thebaut, J.F, Thebaut, P., Vin, F. Etude de lEndotelon
dand les manifestations fonctionnelles de linsuffisance veineuse
peripherique-resultats dune etude en double aveugle portant sur
92 patients. Gazette Medicale, (92)1, 1985. pp. 96-100.
65. Wegrowski, J., Robert, A.M., Maczar, M. Biochem.
Pharmacol, (33)21. 1984. pp. 3491-3497.
66. Chang, W.C., Hsu, F.L. Inhibition of platelet aggregation
and arachidonate metabolism in platelets by procyanidins. Prostagland
Leukotri Essent Fatty Acids, 38:181-8, 1989.
67. Masquelier, J. Pycnogenols: recent advances in the
therapeutical activity of procyanidins. Supplement of Planta Medica,
Journal of Medicinal Plant Research and Journal of Natural Products,
July 1980 pp. 243-256.
68. Henning, B., et al. Lipid peroxidation and endothelial
cell injury: implications in atherosclerosis. Free Rad Path & Med,
(4)1988 pp. 99-106.
69. Masquelier, J. Les procyanidols du vin leur
role dans lalcoolisme. pp. 88-93.
70. Gazave, J.M. Notions recentes sur les capillaires
unpub. bulletin from the Laboratoire De Physiologie Patholigie pp. 26-29.
71. Ruf, J.C. Wine and polyphenols related to platelet
aggregation and atherothrombosis. Office International Vigne et du Vin,
Nutrition and Health Unit, Paris France; Drugs under Experimental and
Clinical Research (Switz.) 25/2-3 (125-131), 1999.
72. Blaszo, G. Gabor, M. Oedema-inhibiting effect of
procyanidin. Acta Physiologica Academiae Scientiarum Hungaricae, Tomus
56(2):235-240, 1980.
73. Tayau, M.F, LeFevre, G. Action du leucocyanidol sur
lhyalaluronidase. Bull Soc Pharm Bordeaux, 95:132-136, 1956.
Lamy, M. Utilization des oligomeres procyanidoliques en gynecologie.
Essai Therapeutique Tomel (14) Sept. 2, 1981. pp. 1021-22.
74. Henriet, J.P Une Etude Exemplaire Pour Un Phlebotrope:
letude EIVE. Unpub., pp. 77-83.
75. Pfister, A., Simon, M.T., Gazave, J.M. Sites de fixation
des oligomeres procyanidoliques dans la paroi des capillaires sanguins
du poumon decobaye. Acta Therapeutica (8) 1982. pp. 223-237.
76. Kuttan, R., Donnelly, P., Di Ferrante, N. Collagen
treated with (+) -catechin becomes resistant to the action of mammalian
collagenase. Laboratory of Connective Tissue Research, Dept. of
Biochem. Baylor Col. of Med., Houston TX. 28, May, 1980.
77. Gendre, P., Laparra, J., Barraud, E. Effect
protecteur des oligomeres procyanidoliques sur le lathyrisme experimental
chez le rat. Ann. Pharm. Francaises, (43)1, 1985 pp. 61-73.
78. Corbe, C., Boissin, J.P., Siou, A. Light vision and
chorioretinal circulation. Study of the effect of procyanidolic oligomer
(Endotelon). Jn. Fr. Opthalmol, (11)5:453-460, 1988.
79. Boissin, J.P., Corbe C., Siou, A. Chorioretinal circulation
and dazzling: use of procyanidol oligomers (Endotelon). Bull Soc Ophtalmol
Fr, 88(2):173-4, 177-9, 1988.
80. Proto, F. et al. Electrophysical study of vitis vinifera
procyanoside oligomers effects on retinal function in myopic subjects.
Ann Ott Clin Ocul, 114:85-93, 1988.
81. Saracco, J.B., Estachy, G.M. Etude d lEndotelon
en opthalmologie. Gaz Med de France, 88:2035-2038, 1981.
82. Scharrer, A., Ober, M. Anthocyanosides in the treatment
of retinopathies. Klin Monatsbl Augenheilkd, 178:386-389, 1981.
83. Corbe, C., et al. Microangiopathy of the retina.
J. Fr. Opthalmol, 11:453, 1988.
84. Verin, M.M., Vildy, A., Maurin, J.F., Retinopathies
et O.P.C. Bordeaux Medicale, (16)11. pp. 1467-74, 1978.
85. Soyeux, A. et al. Endotelon. Diabetic retinopathy
and hemorheology. Bull Soc Ophtalmol Fr. 87(12):1441-4, 1987.
86. Fromantin, M. Les oligomeres procyanidoliques
dans le traitement de la fragilite capillaire et de la retinopathie
chez les diabetiques. A propos de 26 cas. Med Int, 16(11):432-434,
Nov. 1981.
87. Arne, J.L. Contribution a letude des oligomeres
procyanidoliques: Endotelon, dans la retinopathie diabetique (a propos
de 30 observations). Gaz. Med. de France, Vol. 89, No. 30, Oct. 8, 1982.
88. Baruch, J. Effect of Endotelon in postoperative edema.
Results of a double-blind study versus placebo in 32 female patients.
Ann Chir Plast Esthet 29(4):393-5, 1984.
89. Rao, C.N. et al. Influence of bioflavonoids on the
collagen metabolism in rats with adjuvantinduced arthritis. Ital J Biochem.
30:54-62, 1981.
90. Gabor, M. Pharmacologic effects of flavonoids on
blood vessels. Angiologica, 9:355-374, 1972.
91. Havsteen, B. Flavonoids, a class of natural products
of high pharmacological potency. Biochem Pharmacol, 32:1141-48, 1983.
92. Reimann, H.J., Lorenz, W., Fischer, M., Frölich,
R., Meyer, H.J. Berkhauser Verlag, Vol. 7/1, Univ. of Marburg/Lahn,
Ger., 1977.
93. Masquelier, J. Action protectrice du vin sur lulcere
gastrique. Resultats, p. 61.
94. Amella, M., et al. Inhibition of mast cell histamine
release by flavonoids and bioflavonoids. Planta Medica, 5116-20, 1985.
95. Packer, L., et al. The antioxidant miracle: your
complete plan. John Wiley & Sons, Inc., 1999.
96. Shaw, R. How [Australian] PycnoGenol [MASQUELIERs®]
Helps Sports People.
97. Masquelier, J. Procyanidolic oligomers (leucocyanidins).
Parfums Cosmet Arom 95:89-97, 1990.
98. Pecking, A., Desprez-Curely, J.P., Megret, G. Oligomers
procyanidoliques (Endotelon) dans le traitement des lymphoedemes post-therepeutiques
de members superieurs. Symposium Satellite, Congres International dAngiologie,
Toulouse, France, 4-7 Oct. 1989.
99. Fahey, T.D., Pearl M. Hormonal effects of phosphatidylserine
during 2 weeks of intense training. Abstract submitted to national meeting
of the Amer College of Sports Medicine, June 1998.
100. Monteleone, P., Maj, M., Beinat, L., Natale, M.,
Kemali, D. Blunting by chronic phosphatidylserine administration of
the stress-induced activation of the hypothalamo-pituitary-adrenal axis
in healthy men. Eur J Clin Pharm 43: 385388, 1992.
101. Fahey, T.D., et al. The hormonal and perceptive
effects of phosphatidylserine administration during two weeks of resistive
exercise-induced overtraining. Bio of Sport 15(3):135-44, 1998.
102. Laparra, J., Michaud, J. Masquelier, J. Action des
oligomeres procyanidoliques sur le cobaye carence en vitamin c. Tavaux
Originaux, University of Bordeaux, 1976.
103. Masquelier, J. Action comparee de divers facteurs
vitaminiques p sur loxydation de lacide ascorbique par les
ions cuivriques. Bull. de la Societe de Chimie Biologique XXXIII (3-4)
1951. pp. 302-304.
104. Masquelier, J. Action comparee de divers facteurs
vitaminiques p sur lacide ascorbique-oxydase. Bull. de la Societe
de Chimie Biologique XXXIII (3,4) 1951. pp.304-306
105. Kakegawa, H., Matsumoto, H., Endo, K., Satoh, T.,
Nonaka, G., Mishioka, I. Inhibitory effects of tannins on hyaluronidase
activation and on the degranulation from rat mesentery mast cells.
Chem. Pharm. Bull. 33(11)1985. 5079-5082.
106. Reiman, H.J., Lorenz, M., Fischer, R., Frolich,
H., Meyer, J. Histamine and acute haemorrhagic lesions in rat
gastric mucosa: prevention of stress ulcer formulation by (+)-catechin,
an inhibitor of specific histidine decarboxylase in vitro. Dirkhauser
Verlag,Vol. 7/1, 1977.
107. Pariente, J.J. Parientl-Amsellem, J. Les oedemes
post-traumatoqies chez le sportif: essai controle de lEndothelon.
Actualite Therapeutique 90(3) 2/11 1983 pp. 231-235.
108. Masquelier, J., et al. Flavonoids et Pycnogenols
Int J Vit Nut Res, (49)3:307-311, 1979.
109. Yu, C. L. et al. Mutagenicity of proanthocyanidins.
Food Chem. Toxicol. 25(2):135-9, 1987.
110. Pantaleoni, G.C., Quaglino, D. Univerisity of Aquila
Pharmacol-Toxicologica Report, 1971.
111. Laparra, J., et al., Acta Therapeutica, 4:233, 1978.
112. Volkner, Wolfgang Muller, Ewald, Micronucleus assay
in bone marrow cells of the mouse with Pycnogenol. Cytotest Cell Research
GmbH & Co., projects 143010 & 143021; Feb. 1989.
113. Acute and chronic toxicity tests. International
Bio-Research, Inc., Hanover, Germany, 1967-1971.
114. Dumon, M., Michaud, J., Masquelier, J. Proanthocyanidin
content in vegetable extracts to be used in the preparation of medicines.
Bull. Soc. Pharm. Bordeaux, 129:51-65, 1990.
115. Carper, J., Miracle Cures : Dramatic New Scientific
Discoveries Revealing the Healing Powers of Herbs, Vitamins, and Other
Natural Remedies, HarperCollins Publishers, 1998.
116. Philpott, W.H., Kalita, D.K., et al., Brain Allergies:
The Psychonutrient Connection, Keats Publishing, 1980.
117. Journal of the American Medical Association report
on meeting of experts on the subject of food and behavior. Conclusions
from this conference were summarized as follows: "Dietary pharmacology
is no longer at the fringe of medicine ... Foods do affect behavior.
Foods do affect the brain." JAMA 254:4, Dec. 27, 1985.
118. Wender, E.H., Solanto, M.V., "Effects of sugar
on aggressive and inattentive behavior in children with attention deficit
disorder with hyperactivity and normal children." Pediatrics, 1991
Nov; 88 (5): 960-6.
119. Kaneko, M., et al., "Hypothalamic-putuitary-adrenal
axis function in children with attention deficit hyperactivity disorder."
120. The Journal of Autism and Developmental Disorders,
1993 Mar; 23 (1): 59-65.
121. Vatz, R.E., professor at Towson State University,
and Weinberg, L.S., of the University of Pittsburg, "Attention
Deficit Delirium," Wall Street Journal, July 27, 1994.
122. Physicians Desk Reference® (PDR®), 53rd
Edition, Medical Economics Company.
123. Breggin P.R., Director, Int Cntr for the Study of
Psychiatry and Psychology; Testimony Before the Subcommittee on Oversight
and Investigations Committee on Education and the Workforce U.S. House
of Representatives, September 29, 2000.
124. Breggin, P.R., "Psychostimulants in the treatment
of children diagnosed with ADHD: Risks and mechanism of action,"
International Journal of Risk and Safety in Medicine, 12, 3-35, 1999.
125. Lambert, N., "Stimulant treatment as a risk
factor for nicotine use and substance abuse," Program and Abstracts,
191-8, 1998. NIH Consensus Development Conference Diagnosis and Treatment
of Attention Deficit Hyperactivity Disorder. November 16-18, 1998. William
H. Natcher Conference Center. National Institutes of Health. Bethesda,
Maryland.
126. American Academy of Pediatrics, "Practice guideline:
Diagnosis and evaluation of a child with attention-deficit/hyperactivity
disorder," Pediatrics, 105, 1158-70, 2000.
127. Hallowell, E.M., Ratey, J.J., "Driven to Distraction:
Recognizing and Coping With Attention Deficit Disorder," Simon
& Schuster, 1995.
128. Campbell, L.R., and Cohen, M., "Management
of Attention Deficit Hyperactivity Disorder: A Continuing Dilemma for
Physicians and Educators," Clinical Pediatrics, March, 1990, 29:
191-3.
129. Balch, J.F., "The Super Antioxidants - Why
They Will Change The Face of Healthcare in the 21st Century," M.
Evans and Company, Inc., 1998.
130. Passwater, R., Avery Publishing.
131. Weintraub, S., "Natural Treatments for ADD
and Hyperactivity," Woodland Publishing, 1997.
132. Diller, L.H., "Running On Ritalin: A Physician
Reflects on Children, Society, and Performance in a Pill," Bantam
Books, 1998, 42-43.
133. Reichenberg-Ullman, J., Ullman, R., "Ritalin
Free Kids: Safe and Effective Homeopathic Medicine for ADD and Other
Behaviorial and Learning Problems," Prima Health Publishing, 1996.
134. "Ritalin Finding Its Way Into the Schoolyard,"
Seattle Times, February 9, 1996; idem.
135. "A Risky Rx for Fun," Newsweek, October
30, 1995, 74; idem.
136. Adesman, A.R., Wender, E.H. "Helping the Hyperactive
Child," Patient Care, March 30, 1992, 96-116.
137. Wender, P.H., Attention Deficit Disorder in Adults,
New York/Oxford: Oxford University Press, 1995, 166.
138. Swanson, J.M., et al., "Effect of Stimulant
Medication on Children with Attention Deficit Disorder: A Review of
Reviews," Exceptional Children, 60, 1993: 154-162.
139. Bhagavan, H.N., Coleman, M., Coursin, D.B."The
effect of pyridoxine hydrochloride on blood serotonin and pyridoxal
phosphate contents in hyperactive children." Pediatrics 1975;55:
437-41.
140. Martineau, J., Barthelemy, C., Garreau, B., Lelord,
G. "Vitamin B6, magnesium, and combined B6-Mg: therapeutic effects
in childhood autism." Biological Psychiatry 1985;20:467-78
141. Dolphin, et al (eds). Vitamin B6: Pyridoxal Phosphate.
Toronto: John Wiley & Sons, 1986, chapter 17.
142. The International Nutrition Company Special Report:
"Masquelier's Original OPCs and 10 grape seed extracts: An Independent
State of the Art Comparative Analysis," November 1997.
143. Vogel, J., "A Stress Test for Children; Is
Your 'Problem Child's' Problem Nutrition?", Keats Publishing, 1983.
144. Langseth, L., Dowd, J., "Glucose tolerance
and hyperkinesis," Food and Cosmetic Toxicology, 16 August 1977.
145. Monkeberg, F., Schrimshaw, N.S., Gordon, J.E., et
al., "Effect of early marasmic malnutrition on subsequent physical
and psychological development," Malnutrition, Learning and Behavoir,
Cambridge, Mass.: MIT Press, 1968.
146. Crook, W.G.,"Can a What a Child Eats Make Him
Dull, Stupid or Hyperactive?", Journal of Learning Disabilities,
13:53-58, 1980.
147. Egger, J., et al., "Controlled Trial of oligoantigenic
treatment in the hyperkinetic syndrome, Lancet, 1985 Mar 9: 540-5.
148. Kidd, P., "Phospholipids: life's buildling
blocks.&q148uot; Vitamin Retailer, Oct. 2002.
149. Benton, D, et al., Nutr Neurosci 2001;4;169.
150. Kidd, P., Total Health 2002;24: Resource Guide,
May-June.